These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24110638)

  • 1. Engineered virus-like nanoparticle heparin antagonists.
    Udit AK
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():4118-20. PubMed ID: 24110638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin antagonism by polyvalent display of cationic motifs on virus-like particles.
    Udit AK; Everett C; Gale AJ; Reiber Kyle J; Ozkan M; Finn MG
    Chembiochem; 2009 Feb; 10(3):503-10. PubMed ID: 19156786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyvalent Hybrid Virus-Like Nanoparticles with Displayed Heparin Antagonist Peptides.
    Choi JM; Bourassa V; Hong K; Shoga M; Lim EY; Park A; Apaydin K; Udit AK
    Mol Pharm; 2018 Aug; 15(8):2997-3004. PubMed ID: 29902009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.
    Gale AJ; Elias DJ; Averell PM; Teirstein PS; Buck M; Brown SD; Polonskaya Z; Udit AK; Finn MG
    Thromb Res; 2011 Oct; 128(4):e9-13. PubMed ID: 21496885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin Binding to an Engineered Virus-like Nanoparticle Antagonist.
    Cheong HY; Groner M; Hong K; Lynch B; Hollingsworth WR; Polonskaya Z; Rhee JK; Baksh MM; Finn MG; Gale AJ; Udit AK
    Biomacromolecules; 2017 Dec; 18(12):4113-4120. PubMed ID: 28949131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directed polyvalent display of sulfated ligands on virus nanoparticles elicits heparin-like anticoagulant activity.
    Mead G; Hiley M; Ng T; Fihn C; Hong K; Groner M; Miner W; Drugan D; Hollingsworth W; Udit AK
    Bioconjug Chem; 2014 Aug; 25(8):1444-52. PubMed ID: 24960223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutilation of RNA phage Qbeta virus-like particles: from icosahedrons to rods.
    Cielens I; Ose V; Petrovskis I; Strelnikova A; Renhofa R; Kozlovska T; Pumpens P
    FEBS Lett; 2000 Oct; 482(3):261-4. PubMed ID: 11024472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bio-layer interferometry of a multivalent sulfated virus nanoparticle with heparin-like anticoagulant activity.
    Groner M; Ng T; Wang W; Udit AK
    Anal Bioanal Chem; 2015 Jul; 407(19):5843-7. PubMed ID: 25957844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional virus-based polymer-protein nanoparticles by atom transfer radical polymerization.
    Pokorski JK; Breitenkamp K; Liepold LO; Qazi S; Finn MG
    J Am Chem Soc; 2011 Jun; 133(24):9242-5. PubMed ID: 21627118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metal- and metallocycle-binding sites engineered into polyvalent virus-like scaffolds.
    Udit AK; Hollingsworth W; Choi K
    Bioconjug Chem; 2010 Feb; 21(2):399-404. PubMed ID: 20092295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structures of Qβ virions, virus-like particles, and the Qβ-MurA complex reveal internal coat proteins and the mechanism of host lysis.
    Cui Z; Gorzelnik KV; Chang JY; Langlais C; Jakana J; Young R; Zhang J
    Proc Natl Acad Sci U S A; 2017 Oct; 114(44):11697-11702. PubMed ID: 29078304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric cryo-EM structure of the canonical Allolevivirus Qβ reveals a single maturation protein and the genomic ssRNA in situ.
    Gorzelnik KV; Cui Z; Reed CA; Jakana J; Young R; Zhang J
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):11519-11524. PubMed ID: 27671640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell targeting with hybrid Qβ virus-like particles displaying epidermal growth factor.
    Pokorski JK; Hovlid ML; Finn MG
    Chembiochem; 2011 Nov; 12(16):2441-7. PubMed ID: 21956837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Functionalized Bacteriophage Qβ as a Photocaged Drug Carrier.
    Chen Z; Li N; Chen L; Lee J; Gassensmith JJ
    Small; 2016 Sep; 12(33):4563-71. PubMed ID: 27351167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assembly of bacteriophage Qbeta virus-like particles in yeast Saccharomyces cerevisiae and Pichia pastoris.
    Freivalds J; Dislers A; Ose V; Skrastina D; Cielens I; Pumpens P; Sasnauskas K; Kazaks A
    J Biotechnol; 2006 May; 123(3):297-303. PubMed ID: 16406160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist.
    Cushing DJ; Cooper WD; Cohen ML; McVoy JR; Sobel M; Harris RB
    Eur J Pharmacol; 2010 Jun; 635(1-3):165-70. PubMed ID: 20307530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro neutralization of heparin in plasma prior to the activated partial thromboplastin time test: an assessment of four heparin antagonists and two anion exchange resins.
    Cumming AM; Jones GR; Wensley RT; Cundall RB
    Thromb Res; 1986 Jan; 41(1):43-56. PubMed ID: 3961726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-Derived Nanoparticles.
    Dashti NH; Sainsbury F
    Methods Mol Biol; 2020; 2073():149-162. PubMed ID: 31612441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.
    Kalaska B; Kaminski K; Sokolowska E; Czaplicki D; Kujdowicz M; Stalinska K; Bereta J; Szczubialka K; Pawlak D; Nowakowska M; Mogielnicki A
    PLoS One; 2015; 10(3):e0119486. PubMed ID: 25781030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of heparin antagonists with focused biological activity.
    Shenoy S; Harris RB; Sobel M
    Curr Pharm Des; 1999 Dec; 5(12):965-86. PubMed ID: 10607857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.